This study investigated the 1-year incidence of extrapyramidal symptoms (EPS), as well as the incremental economic burden, in patients with schizophrenia initiating atypical antipsychotics.
Brenna L. Brady, PhD
Advertisement
Articles by Brenna L. Brady, PhD
Advertisement
Latest Updated Articles
- Burden of EPS in Commercial Patients With Schizophrenia Initiating Atypical Antipsychotics
Published: June 3rd 2022 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
New Legislation Aims to Address Transparency in PBMs as First Major Step in Reform
3
Overcoming Mistrust in Clinical Trial Enrollment Through Community Resources: Susan Vadaparampil, PhD, MPH
4
Medicare’s 3-Day Rule Reinstatement Lengthened Hospital Stays Without Cost, Outcome Benefits
5